SCHEMBL6415669

SCHEMBL6415669

O=[N+]([O-])c1ccc(-c2ccc(C=NNc3nc4nonc4nc3Nc3ccc(F)cc3)o2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.53
MEN1 O00255 11/20 0.53
GAA P10253 4/20 0.53
RECQL P46063 2/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 14/20 0.49
ALDH1A1 P00352 5/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
CRHBP P24387 2/20 0.49
CRHR2 Q13324 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HTT P42858 1/20 0.48
BLM P54132 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 3/20 0.46
PSMD14 O00487 1/20 0.45
BIRC5 O15392 1/20 0.44
PHGDH O43175 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415667 1.00 KMT2A (0.53) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6507696 0.90 MAPT (0.52) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6507700 0.90 MAPT (0.52) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6506319 0.87 MET (0.52) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6503291 0.87 MET (0.52) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6435673 0.86 MEN1 (0.48) KMT2AMEN1GAAKDM4EMAPT
SCHEMBL6505849 0.86 BIRC5 (0.53) KMT2AMEN1GAAKDM4EMAPT
SCHEMBL6505842 0.86 BIRC5 (0.53) KMT2AMEN1GAAKDM4EMAPT
SCHEMBL6419740 0.85 BIRC5 (0.57) KMT2AMEN1GAARECQLKDM4E
SCHEMBL6419733 0.85 BIRC5 (0.57) KMT2AMEN1GAARECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 KMT2A 3640/4885MEN1 4392/4885GAA 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.